CRH (CRH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
Announces intention to delist ordinary and 7% preference shares from the London Stock Exchange and cancel 5% and 7% preference shares, subject to shareholder approval.
Delisting and cancellations are aimed at reducing costs and regulatory burdens, following a review of trading activity and capital structure.
Preference share cancellations will be exchanged for cash payments, with values set at €2.54 per 5% share and €3.556 per 7% share, representing 200% and 280% of nominal value, respectively.
Last day of LSE trading for ordinary shares is April 17, 2026; delisting effective April 20, 2026; preference share cancellations expected mid-2026, pending approvals.
Forward-looking statements caution on risks, including shareholder approval and potential unexpected costs.
Voting matters and shareholder proposals
Shareholders will vote on the proposed cancellation of 5% and 7% preference shares at the 2026 AGM on May 7, 2026, and at separate meetings for preference shareholders on May 21, 2026.
Proxy materials, including FAQs, will be provided to assist shareholders in making informed voting decisions.
Board of directors and corporate governance
Directors, executive officers, and certain employees may participate in proxy solicitation for the preference share cancellations.
Information on directors and executive officers is available in prior SEC filings and will be included in the definitive proxy statement.
Latest events from CRH
- Record financials, capital structure simplification, and key governance proposals for 2026 AGM.CRH
Proxy Filing13 Mar 2026 - Record 2025 financials, double-digit EBITDA growth, and strong 2026 outlook on infrastructure demand.CRH
Q4 202519 Feb 2026 - Q2 net income up 8%, EBITDA up 12%, margins expanded, and FY24 guidance raised.CRH
H1 20242 Feb 2026 - Q3 saw strong sales, margin gains, and M&A, with a positive outlook reaffirmed.CRH
Q3 2024 TU16 Jan 2026 - Double-digit profit growth and margin expansion achieved, with strong 2025 outlook.CRH
H2 20247 Jan 2026 - Record Q3, raised FY25 EBITDA guidance, and strong outlook driven by demand and acquisitions.CRH
Q3 2025 TU21 Dec 2025 - Record financials, new equity plan, governance updates, and strong ESG progress headline the proxy.CRH
Proxy Filing2 Dec 2025 - Record results, NYSE transition, new CEO, and 12 key AGM proposals mark a transformative year.CRH
Proxy Filing2 Dec 2025 - Definitive additional proxy materials filed for upcoming shareholder meeting.CRH
Proxy Filing2 Dec 2025